Biomolecular Facility Core

$55,351P30FY2016ESNIH

University Of Texas Med Br Galveston, Galveston TX

Investigators

Linked publications & trials

Paper 37446098 Paper 36513449 Paper 34139550 Paper 34127701 Paper 33718601 Paper 32693175 Paper 32387285 Paper 32205441 Paper 31590776 Paper 31535213 Paper 31424945 Paper 31211863 Paper 30986815 Paper 30844571 Paper 30798701 Paper 30439292 Paper 30277801 Paper 30240697 Paper 30240635 Paper 30190498 Paper 30180781 Paper 30161008 Paper 30153047 Paper 29940424 Paper 29789500 Paper 29694891 Paper 29642012 Paper 29593031 Paper 29452288 Paper 29337245 Paper 29330301 Paper 29302691 Paper 29232306 Paper 29197527 Paper 29183775 Paper 29088124 Paper 29035516 Paper 28939775 Paper 28818856 Paper 28792616 Paper 28726418 Paper 28714690 Paper 28696214 Paper 28609370 Paper 28581456 Paper 28278373 Paper 28266569 Paper 28258195 Paper 28215221 Paper 28182006 Paper 28082109 Paper 28077651 Paper 27918196 Paper 27911568 Paper 27798657 Paper 27793799 Paper 27756845 Paper 27742828 Paper 27703167 Paper 27662828 Paper 27571429 Paper 27535058 Paper 27461979 Paper 27343030 Paper 27239029 Paper 26917740 Paper 26783425 Paper 26756522 Paper 26721307 Paper 26694039 Paper 26588813 Paper 26581097 Paper 26560068 Paper 26472195 Paper 26424795 Paper 26423835 Paper 26395544 Paper 26392023 Paper 26339600 Paper 26245904 Paper 26209609 Paper 26187872 Paper 26187636 Paper 26073125 Paper 26023251 Paper 25953917 Paper 25922579 Paper 25862520 Paper 25740991 Paper 25728087 Paper 25672339 Paper 25645280 Paper 25633985 Paper 25614460 Paper 25520509 Paper 25486379 Paper 25267977 Paper 25250913 Paper 25132995 Paper 25043449

Abstract

The BRF provides a research-related infrastructure to the UTMB-CET and research community at large that includes high-quality analytical and preparative services relating to biomolecules (proteins, peptides). In addition to the established technologies described in the BRF Facility Core write-up, some novel methodologies available or under development are: ? For proteomics-based biomarker discovery, a multi-tiered platform capability developed at UTMB based on sensitive 2DE platforms, and stable isotopic labeling for mass spectrometry, which permits the identification and validation of protein or peptide disease biomarkers (Dr. Garofalo, Pediatrics). ? The NHLBI Proteomics Center has established a core for quantitation of cytokine concentrations using Luminex xMAP assays on human samples. These assays rival conventional ELISA in sensitivity, but can simultaneously quantify up to 25 cytokines in a single sample (Dr. Brasier, Internal Medicine).

View original record on NIH RePORTER →